Vest Prevention of Early Sudden Death Trial and VEST Registry

In patients with ventricular dysfunction immediately following myocardial infarction, sudden
death may be responsible for up to 50% of total mortality. Wearable defibrillators may reduce
sudden death by providing immediate detection and treatment of ventricular arrhythmias. This
study is design to demonstrate a reduction in sudden death measured at three months following
myocardial infarction among patients who have ventricular dysfunction.

Inclusion Criteria:

- Patients identified in the hospital or within 7 days after discharge with a diagnosis
of an acute MI (STEMI or Non-STEMI)

- LV ejection fraction ≤35% determined at the following time point:

1. If no PCI within the first 8 hours following the MI: ≥ 8 hours after MI

2. If acute PCI occurs within 8 hours of MI: ≥8 hours after PCI

3. If CABG is planned (before or within 7 days of discharge), wait to enroll and
then use the most recent assessment at least 48 hours post CABG

- Age ≥ 18 years

Exclusion Criteria:

- Existing ICD or indication for an ICD at the time of screening

- Existing unipolar pacemakers/leads

- Chronic renal failure requiring hemodialysis after hospital discharge

- Chest circumference too small or too large for LifeVest garment*

- Participants discharged to an institutional setting with an anticipated stay > 7 days

- Pregnancy

- Inability to consent

- Any other condition or circumstance that in the judgment of the clinician makes the
participant unsuitable for the study.